

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10522321
	Filing Date	2005-07-06
	First Named Inventor	BIGGADIKE, et al.
	Art Unit	1625
	Examiner Name	Aulakh, Charanjhit
	Attorney Docket Number	PG4858USw

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/CA/	1	3994974		1976-11-30	Murakami et al.	
/CA/	2	4730008		1988-03-08	Skidmore, et al.	
/CA/	3	4853381		1989-08-01	Finch et al.	
/CA/	4	4853382		1989-08-01	Skidmore, et al.	
/CA/	5	4908386		1990-03-13	Finch et al.	
/CA/	6	4937268		1990-06-26	Skidmore, et al.	
/CA/	7	4963564		1990-10-16	Skidmore, et al.	
/CA/	8	4990505		1991-02-05	Skidmore, et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10522321
Filing Date		2005-07-06
First Named Inventor	BIGGADIKE, et al.	
Art Unit	1625	
Examiner Name	Aulakh, Charanjhit	
Attorney Docket Number	PG4858USw	

/CA/	9	4992474		1991-02-12	Skidmore, et al.	
/CA/	10	4997986		1991-03-05	Mitchell, et al.	
/CA/	11	5099068		1992-03-24	Mitchell, et al.	
/CA/	12	5109023		1992-04-28	Mitchell, et al.	
/CA/	13	5283262		1994-02-01	Mitchell, et al.	
/CA/	14	5552438		1996-09-03	Christensen, IV	
/CA/	15	5066678		1991-11-19	Finch et al.	
/CA/	16	6395738		2002-05-28	Ohshima et al.	
/CA/	17	6514996		2003-02-04	Ohshima et al.	
/CA/	18	6716987		2004-04-06	Ohshima et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10522321	
	Filing Date		2005-07-06	
	First Named Inventor		BIGGADIKE, et al.	
	Art Unit		1625	
	Examiner Name		Aulakh, Charanjhit	
	Attorney Docket Number		PG4858USw	

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/CA/	1	2002/012829	A1	2002-09-12	Ohshima et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
/CA/	1	69715	EP		1983-01-12	Aktiebolaget Draco		<input type="checkbox"/>
/CA/	2	220878	EP		1987-05-06	Glaxo Group Limited		<input type="checkbox"/>
/CA/	3	223410	EP		1987-05-27	Glaxo Group Limited		<input type="checkbox"/>
/CA/	4	286242	EP		1988-10-12	Glaxo Group Limited		<input type="checkbox"/>
/CA/	5	303465	EP		1989-02-15	Glaxo Group Limited		<input type="checkbox"/>
/CA/	6	317206	EP		1989-05-24	Glaxo Group Limited		<input type="checkbox"/>
/CA/	7	416951	EP		1991-03-13	Glaxo Group Limited		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10522321
	Filing Date	2005-07-06
	First Named Inventor	BIGGADIKE, et al.
	Art Unit	1625
	Examiner Name	Aulakh, Charanjhit
	Attorney Docket Number	PG4858USw

/CA/	8	2064336	GB		1981-06-17	Glaxo Group Limited		<input type="checkbox"/>
/CA/	9	2129691	GB		1984-05-23	Glaxo Group Limited		<input type="checkbox"/>
/CA/	10	2159151	GB		1985-11-27	Glaxo Group Limited		<input type="checkbox"/>
/CA/	11	2162842	GB		1986-02-12	Glaxo Group Limited		<input type="checkbox"/>
/CA/	12	2169265	GB		1986-07-09	Glaxo Group Limited		<input type="checkbox"/>
/CA/	13	2178965	GB		1987-02-25	Glaxo Group Limited		<input type="checkbox"/>
/CA/	14	2242134	GB		1991-09-25	Glaxo Group Limited		<input type="checkbox"/>
/CA/	15	416951	GB		1991-09-01	Hobbs, et al.		<input type="checkbox"/>
/CA/	16	95/01170	WO		1995-01-12	Glaxo Group Limited		<input type="checkbox"/>
/CA/	17	99/16766	WO		1999-04-08	Ohshima, et al.		<input type="checkbox"/>
/CA/	18	99/47505	WO		1999-09-23	Hatzelmann, A., et al.		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10522321	
	Filing Date		2005-07-06	
	First Named Inventor	BIGGADIKE, et al.		
	Art Unit	1625		
	Examiner Name	Aulakh, Charanjhit		
	Attorney Docket Number	PG4858USw		

/CA/	19	01/13953	WO		2001-03-01	Beume, R., et al.		<input type="checkbox"/>
------	----	----------	----	--	------------	-------------------	--	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
/CA/	1	THORNER, C.W.; Isosterism and Molecular Modification in Drug Design; Chemical Society Reviews; 1979; Vol. 8, Iss. 4; pp. 563-580;	<input type="checkbox"/>
/CA/	2	IAKOVIDIS, D. ET AL.; Synthesis and beta-andrenoceptor agonist properties of (+/-)-1-(3',4'-dihydroxyphenoxy)-3-(3",4"-dimethoxyphenyl)ethylamino-2-propanol hydrochloride, (+/-)-RO363.HCl, and the (2S)-(-)-isomer"; European Journal of Medicinal Chemistry; 1999; Vol. 34, No. 6; pp. 539-548;	<input type="checkbox"/>
/CA/	3	FUJI ET AL.; Novel phosphodiesterase 4 inhibitor T-440 reverse and prevents human bronchial contraction induced by allergen.; Journal of Pharmacology and Experimental Therapeutics; 1998; Vol. 284, No. 1; pp. 162-169;	<input type="checkbox"/>
/CA/	4	LANDELLS, ET AL.; Oral administration of the phosphodiesterase (PDE)4 inhibitor, V11294 inhibits ex-vivo agonist-induced-cell activation.; European Respiratory Journal (Annu Cong Eur Resp Soc, Geneva); 1998; Vol. 12, Suppl. 28; Abst P2393;	<input type="checkbox"/>
/CA/	5	MCHALE, M.M.ET AL.; Expression of Human Recombinant cAMP Phosphodiesterase Isozyme IV Reverses Growth Arrest Phenotypes in Phosphodiesterase-Deficient Yeast; Molecular Pharmacology; 1991; Vol. 39; pp. 109-113;	<input type="checkbox"/>
/CA/	6	NICHOLSON, C. D, ET AL.; Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes; Trends in Pharmacological Sciences; 1991; Vol. 12; pp. 19-27;	<input type="checkbox"/>
/CA/	7	TORPHY, T.J., ET AL.; Role of Cyclic Nucleotide Phosphodiesterase Isozymes in Intact Canine Trachealis; Molecular Pharmacology; 1991; Vol. 39; pp. 376-384;	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10522321
	Filing Date	2005-07-06
	First Named Inventor	BIGGADIKE, et al.
	Art Unit	1625
	Examiner Name	Aulakh, Charanjhit
	Attorney Docket Number	PG4858USw

EXAMINER SIGNATURE			
Examiner Signature	/Charanjit Aulakh/	Date Considered	02/25/2008
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			
<p>¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.</p>			